|
1.
|
Goldhirsch A, Ingle JN, Gelber RD, Coates
AS, Thürlimann B and Senn HJ: panel members:. Thresholds for
therapies: highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann
Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Gerdes J, Schwab U, Lemke H and Stein H:
Production of a mouse monoclonal antibody reactive with a human
nuclear antigen associated with cell proliferation. Int J Cancer.
31:13–20. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Cattoretti G, Becker MH, Key G, Duchrow M,
Schlüter C, Galle J and Gerdes J: Monoclonal antibodies against
recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect
proliferating cells in microwave-processed formalin-fixed paraffin
sections. J Pathol. 168:357–363. 1982. View Article : Google Scholar
|
|
4.
|
Paik S, Shak S, Tang G, et al: A multigene
assay to predict recurrence of tamoxifen-treated, node-negative
breast cancer. N Engl J Med. 351:2817–2826. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Paik S, Tang G, Shak S, et al: Gene
expression and benefit of chemotherapy in women with node-negative,
estrogen receptor-positive breast cancer. J Clin Oncol.
24:3726–3734. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
De Azambuja E, Cardoso F, de Castro G Jr,
et al: Ki-67 as prognostic marker in early breast cancer: a
meta-analysis of published studies involving 12,155 patients. Br J
Cancer. 96:1504–1513. 2007.PubMed/NCBI
|
|
7.
|
Yerushalmi R, Woods R, Ravdin PM, Hayes MM
and Gelmon KA: Ki67 in breast cancer: prognostic and predictive
potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kai K, Nishimura R, Arima N, Miyayama H
and Iwase H: p53 expression status is a significant molecular
marker in predicting the time to endocrine therapy failure in
recurrent breast cancer: a cohort study. Int J Clin Oncol.
11:426–433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wiesner FG, Magener A, Fasching PA, et al:
Ki-67 as a prognostic molecular marker in routine clinical use in
breast cancer patients. Breast. 18:135–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Penault-Llorca F, Andre F, Sagan C, et al:
Ki67 expression and docetaxel efficacy in patients with estrogen
receptor-positive breast cancer. J Clin Oncol. 27:2809–2815. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Clahsen PC, van de Velde CJ, Duval C, et
al: The utility of mitotic index, estrogen receptor and Ki-67
measurements in the creation of novel prognostic indices for
node-negative breast cancer. Eur J Surg Oncol. 25:356–363. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Weikel W, Brumm C, Wilkens C, Beck T and
Knapstein PG: Growth fractions (Ki-67) in primary breast cancers,
with particular reference to node-negative tumors. Cancer Detect
Prev. 19:446–450. 1995.PubMed/NCBI
|
|
14.
|
Petit T, Wilt M, Velten M, et al:
Comparative value of tumour grade, hormonal receptors, Ki-67, HER2
and topoisomerase II alpha status as predictive markers in breast
cancer patients treated with neoadjuvant anthracycline based
chemotherapy. Eur J Cancer. 40:205–211. 2004. View Article : Google Scholar
|
|
15.
|
Mauriac L, MacGrogan G, Avril A, et al:
Neoadjuvant chemotherapy for operable breast carcinoma larger than
3 cm: a unicentre randomized trial with a 124-month median
follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann
Oncol. 10:47–52. 1999. View Article : Google Scholar
|
|
16.
|
Nishimura R, Osako T, Okumura Y, Hayashi M
and Arima N: Clinical significance of Ki-67 in neoadjuvant
chemotherapy for primary breast cancer as a predictor for
chemosensitivity and for prognosis. Breast Cancer. Sept.
4–2009.(E-pub ahead of print).
|
|
17.
|
Cheang MCU, Chia SK, Voduc D, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
|
|
18.
|
Di Leo A, Biganzoli L, Claudino W, Licitra
S, Pestrin M and Larsimont D: Topoisomerase II alpha as a marker
predicting anthracyclines' activity in early breast cancer
patients: ready for the primetime? Eur J Cancer. 44:2791–2798.
2008.
|
|
19.
|
Durbecq V, Desmed C, Paesmans M, et al:
Correlation between topoisomerase-II alpha gene amplification and
protein expression in HER-2 amplified breast cancer. Int J Oncol.
25:1473–1479. 2004.PubMed/NCBI
|
|
20.
|
Caudle AS, Gonzalez-Angulo AM, Hunt KK, et
al: Predictors of tumor progression during neoadjuvant chemotherapy
in breast cancer. J Clin Oncol. 28:1821–1828. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Chang J, Powles TJ, Allred DC, et al:
Prediction of clinical outcome from primary tamoxifen by expression
of biologic markers in breast cancer patients. Clin Cancer Res.
6:616–621. 2000.PubMed/NCBI
|
|
22.
|
Makris A, Powles TJ, Allred DC, et al:
Changes in hormone receptors and proliferation markers in tamoxifen
treated breast cancer patients and the relationship with response.
Breast Cancer Res Treat. 48:11–20. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Dowsett M, Smith IE, Ebbs SR, Dixon JM,
Skene A, A'Hern R, Salter J, Detre S, Hills M and Walsh G; IMPACT
Trialists Group: Prognostic value of Ki67 expression after
short-term presurgical endocrine therapy for primary breast cancer.
J Natl Cancer Inst. 99:167–170. 2007. View Article : Google Scholar
|
